Literature DB >> 18008377

Androgen signaling and its interactions with other signaling pathways in prostate cancer.

Mari Kaarbø1, Tove I Klokk, Fahri Saatcioglu.   

Abstract

Prostate cancer is the most frequently diagnosed non-skin cancer and the third leading cause of cancer mortality in men. In the initial stages, prostate cancer is dependent on androgens for growth, which is the basis for androgen ablation therapy. However, in most cases, prostate cancer progresses to a hormone refractory phenotype for which there is no effective therapy available at present. The androgen receptor (AR) is required for prostate cancer growth in all stages, including the relapsed, "androgen-independent" tumors in the presence of very low levels of androgens. This review focuses on AR function and AR-target genes and summarizes the major signaling pathways implicated in prostate cancer progression, their crosstalk with each other and with AR signaling. This complex network of interactions is providing a deeper insight into prostate carcinogenesis and may form the basis for novel diagnostic and therapeutic strategies. 2007 Wiley Periodicals, Inc

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18008377     DOI: 10.1002/bies.20676

Source DB:  PubMed          Journal:  Bioessays        ISSN: 0265-9247            Impact factor:   4.345


  34 in total

Review 1.  Androgen receptor (AR) positive vs negative roles in prostate cancer cell deaths including apoptosis, anoikis, entosis, necrosis and autophagic cell death.

Authors:  Simeng Wen; Yuanjie Niu; Soo Ok Lee; Chawnshang Chang
Journal:  Cancer Treat Rev       Date:  2013-08-07       Impact factor: 12.111

Review 2.  In vivo imaging of molecular targets and their function in endocrinology.

Authors:  Joanna E Burdette
Journal:  J Mol Endocrinol       Date:  2008-06       Impact factor: 5.098

3.  Targeting castration-resistant prostate cancer with androgen receptor antisense oligonucleotide therapy.

Authors:  Marco A De Velasco; Yurie Kura; Kazuko Sakai; Yuji Hatanaka; Barry R Davies; Hayley Campbell; Stephanie Klein; Youngsoo Kim; A Robert MacLeod; Koichi Sugimoto; Kazuhiro Yoshikawa; Kazuto Nishio; Hirotsugu Uemura
Journal:  JCI Insight       Date:  2019-09-05

4.  Honokiol inhibits androgen receptor activity in prostate cancer cells.

Authors:  Eun-Ryeong Hahm; A Isabella Karlsson; Michael Y Bonner; Jack L Arbiser; Shivendra V Singh
Journal:  Prostate       Date:  2013-12-11       Impact factor: 4.104

Review 5.  Androgen action in prostate cancer.

Authors:  Sujit Basu; Donald J Tindall
Journal:  Horm Cancer       Date:  2010-10       Impact factor: 3.869

6.  Testosterone membrane-initiated action in breast cancer cells: Interaction with the androgen signaling pathway and EPOR.

Authors:  Vassiliki Pelekanou; George Notas; Elias Sanidas; Andreas Tsapis; Elias Castanas; Marilena Kampa
Journal:  Mol Oncol       Date:  2010-02-02       Impact factor: 6.603

7.  Molecular processes leading to aberrant androgen receptor signaling and castration resistance in prostate cancer.

Authors:  Rong Hu; Samuel R Denmeade; Jun Luo
Journal:  Expert Rev Endocrinol Metab       Date:  2010-09

8.  Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer.

Authors:  Yang Jin; Su Qu; Martina Tesikova; Ling Wang; Alexandr Kristian; Gunhild M Mælandsmo; Haiying Kong; Tianzhou Zhang; Carmen Jerónimo; Manuel R Teixeira; Erkan Yuca; Ibrahim Tekedereli; Kivanc Gorgulu; Neslihan Alpay; Anil K Sood; Gabriel Lopez-Berestein; Håvard E Danielsen; Bulent Ozpolat; Fahri Saatcioglu
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-24       Impact factor: 11.205

9.  Anti-androgen resistance in prostate cancer cells chronically induced by interleukin-1β.

Authors:  Julia A Staverosky; Xin-Hua Zhu; Susan Ha; Susan K Logan
Journal:  Am J Clin Exp Urol       Date:  2013-12-25

10.  Transcriptional repression and inhibition of nuclear translocation of androgen receptor by diallyl trisulfide in human prostate cancer cells.

Authors:  Silvia D Stan; Shivendra V Singh
Journal:  Clin Cancer Res       Date:  2009-07-21       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.